期刊文献+

MTX联合艾拉莫德治疗难治性类风湿关节炎的临床观察 被引量:11

下载PDF
导出
摘要 目的研究甲氨蝶呤联合艾拉莫德对难治性类风湿关节炎的疗效及安全性,并与甲氨蝶呤联合羟氯喹、柳氮磺吡啶进行对照。方法86例难治性类风湿关节炎患者随机分为实验组和对照组,实验组用甲氨蝶呤联合艾拉莫德治疗,对照组用甲氨蝶呤联合羟氯喹、柳氮磺吡啶治疗,疗程24周;对两组在12、24周时的疗效进行评估。结果两组在12、24周时均能显著改善临床症状和实验指标,12周时临床疗效比较无统计学意义,24周时临床疗效比较有统计学意义,提示甲氨蝶呤联合艾拉莫德对难治性类风湿关节炎远期疗效比甲氨蝶呤联合羟氯喹、柳氮磺吡啶好。甲氨蝶呤联合艾拉莫德其耐受性与甲氨蝶呤联合羟氯喹、柳氮磺吡啶无明显差别。结论甲氨蝶呤联合艾拉莫德是难治性类风湿关节炎有效的治疗方案,且较安全。
出处 《中国医药指南》 2014年第1期98-99,共2页 Guide of China Medicine
  • 相关文献

参考文献6

二级参考文献15

  • 1栗占国.风湿性疾病的规范化治疗势在必行[J].北京大学学报(医学版),2006,38(4):341-344. 被引量:6
  • 2Grigor C,Capeli H,Stiding A,et al.Effect of a treatment strategy of fight control for rheumatoid arthritis (The TICORA study):a single-blind randomized controlled trial.Lancet,2004,364:263-269.
  • 3Saag KG,Teng GG,Patkar NM,et al.American College of Rheumatology.American College of Rheumatology 2008 recommendations for the use of nonbiologie and biologic diseasemodifying antirheumatie drugs in rheumatoid arthritis.Arthritis Rheum,2008,59:726-784.
  • 4Rantalaiho V,Korpela M,Hannonen P,et al.FIN-RACo Trial Group.The good initial response to therapy with a combination of traditional disease-modifying antirheumatie drugs is sustained over time:the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial.Arthritis Rheum,2009,60:1222-1231.
  • 5Choy EH,Smith C,DoréCJ,et al.A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal.Rheumatology,2005,44:1414-1421.
  • 6Visser K,Katehamart W,Loza E,et al.Multinational evidencebased recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis:integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiation.Ann Rheum Dis,2009,58:1086-1093.
  • 7Aikawa Y, Tanuma N, Shin T, et al. A new anti-rheumatic drug,T-614, effectively suppresses the development of autoimmune encephalomyelitis. J Neuroimmunol, 1998, 89: 35-42.
  • 8Tanaka K, Yamamoto T, Aikawa Y, et al. Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology, 2003, 42: 1365-1371.
  • 9Tanaka K, Kawasaki H, Kurata K, et al. T-614, a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jap J Pharmacol, 1995, 67: 305.
  • 10Sullivan S. Iguratimod: novel DMARD promising for rheumatoid arthritis. Inpharma, 2004, 7: 1450.

共引文献61

同被引文献110

引证文献11

二级引证文献129

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部